With one drug taking on average 2 billion dollars and 15 years to get to the market, the hunt is on for already existing FDA-approved drugs for purposes (indications) other than those they were approved for. Our lab intends to develop an ‘-omics’ stack that brings together genomics and other genome-scale datasets that is also integrated with clinical data available at our partner hospitals. This rich and integrated corpus of knowledge, using systems biology tools, will enable us to predict 1) new therapeutic targets and pathways and 2) novel and repurposed drug candidates that can enhance cancer patient outcomes in the local population.